Reminder for Geron Investors: Class Action Lawsuit Pending – NEWS10 ABC
Investors who have invested in Geron Corporation (GERN) were recently reminded by Levi & Korsinsky of an ongoing class action lawsuit. The pending lawsuit has a lead plaintiff deadline set for May 12, 2025. Levi & Korsinsky, a national law firm, specializes in representing shareholders in securities litigation and has been actively involved in bringing forth legal actions against various corporations.
Geron Corporation is a biopharmaceutical company focused on the development of innovative cancer treatments. The class action lawsuit against Geron stems from allegations that the company made false and misleading statements regarding the efficacy of its sole drug candidate, imetelstat, as a treatment for essential thrombocythemia (ET) and myelofibrosis (MF). The lawsuit claims that Geron overstated the drug’s potential in treating these conditions, leading to inflated stock prices.
The lead plaintiff deadline of May 12, 2025, is approaching, and investors who wish to participate in the lawsuit must take action before this date. Those who purchased Geron stock between March 19, 2018, and September 26, 2018, are eligible to join the class action lawsuit. By participating in the lawsuit, investors have the opportunity to seek financial compensation for any losses incurred as a result of the alleged misrepresentations made by Geron.
Levi & Korsinsky urge investors to consider their legal rights and options before the lead plaintiff deadline passes. The law firm specializes in representing shareholders who have been victims of securities fraud and aims to hold corporations accountable for their actions. By taking legal action against Geron, investors have the chance to seek justice and potentially recoup financial losses suffered due to the alleged misconduct of the company.
Investors who believe they may have a claim against Geron Corporation are encouraged to contact Levi & Korsinsky before the May 12, 2025, deadline. The law firm offers a free consultation to assess each individual case and determine the best course of action moving forward. By seeking legal representation, investors can take a stand against corporate misconduct and work towards achieving a fair resolution in the ongoing class action lawsuit against Geron.
In conclusion, Levi & Korsinsky has reminded Geron investors of the impending deadline for the class action lawsuit against the company. Allegations of false and misleading statements regarding the efficacy of Geron’s drug candidate have prompted legal action against the biopharmaceutical corporation. Investors who wish to participate in the lawsuit should act before the lead plaintiff deadline of May 12, 2025, to seek financial compensation for any losses suffered due to the alleged misconduct of Geron Corporation. Contacting Levi & Korsinsky for a free consultation can help investors determine their legal rights and options in pursuing justice in the ongoing class action lawsuit.
